Dipotassium Clorazepate

Long-acting benzodiazepine. It is used in the treatment of anxiety disorders and epilepsy. Most of the clorazepate is metabolized to N-desmethyldiazepam (nordiazepam) which is the active metabolite of diazepam.

It is excreted in breast milk in clinically insignificant amounts. ^{(Rey 1979)}

Sedation has been observed in infants whose mothers were taking diazepam. ^{(Wesson 1985)}

Levels that could be significant have been measured in the plasma of infants whose mothers were taking it. ^{(Rey 1979, Wesson 1985)}

Due to the lack of publications on this subject, until more information is known about this drug in relation to breastfeeding, safer known alternatives are preferred, especially in the neonatal period and in case of prematurity. ^{(McElhatton 1994)}

The occasional use and low doses of benzodiazepines are compatible with breastfeeding. ^{(Kelly 2012, Rubin 2004, Iqbal 2002, Hägg 2000, McElhatton 1994, Lee 1993, Kanto 1982)}

It is advisable to choose a short-acting benzodiazepine and minimal effective dose as possible (Rowe 2013), mostly in neonatal period.

Follow-up for sedation and feeding ability of the infant. It is not recommended to share a bed (co-sleeping, bed-sharing) with the baby if this drug is being taken, due to increased risk of asphyxia or sudden infant death. ^{(ABM 2020, UNICEF UK 2018, 2017, 2014 y 2013, Landa 2012, ABM 2008, UNICEF UK 2006)}

See below the information of these related products:

• Maternal Depression (Fairly safe. Mild or unlikely adverse effects. Compatible under certain circumstances. Follow-up recommended. Read Commentary.)
• Maternal Epilepsy (Fairly safe. Mild or unlikely adverse effects. Compatible under certain circumstances. Follow-up recommended. Read Commentary.)